MDC1 and 53BP1 are critical components of the DNA damage response (DDR) machinery that protects genome integrity and guards against cancer, yet the tissue expression patterns and involvement of these two DDR adaptors/ mediators in human tumours remain largely unknown. Here we optimized immunohistochemical analyses of human 53BP1 and MDC1 proteins in situ and identified their virtually ubiquitous expression, both in proliferating and quiescent, differentiated tissues. Focus formation by 53BP1 and/or MDC1 in human spermatogenesis and subsets of breast and lung carcinomas indicated physiological and 'pathological' activation of the DDR, respectively. Furthermore, aberrant reduction or lack of either protein in significant proportions of carcinomas supported the candidacy of 53BP1 and MDC1 for tumour suppressors. Contrary to carcinomas, almost no activation or loss of MDC1 or 53BP1 were found among testicular germ-cell tumours (TGCTs), a tumour type with unique biology and exceptionally low incidence of p53 mutations. Such concomitant presence (in carcinomas) or absence (in TGCTs) of DDR activation and DDR aberrations supports the roles of MDC1 and 53BP1 within the ATM/ATR-regulated checkpoint network which, when activated, provides an early anticancer barrier the pressure of which selects for DDR defects such as p53 mutations or loss of 53BP1/MDC1 during cancer progression.
Introduction
Maintenance of genomic integrity and protection against harmful mutagenic effects of DNA damage rely on DNA damage response machinery, a complex network of signalling and effector pathways that coordinate cell cycle checkpoints with DNA repair and cell death mechanisms (Shiloh, 2003; Kastan and Bartek, 2004; Lukas et al., 2004b; Bartek and Lukas, 2007) . In response to DNA lesions, cells activate the apical signalling kinases ATM, ATR or DNA-PK (Shiloh, 2003; Bakkenist and Kastan, 2004) , which then phosphorylate a plethora of substrates within the DNA damage response (DDR) network, including the effector kinases Chk1 and Chk2 that become activated upon their phosphorylations by ATR and ATM, respectively, and further amplify and spread the alert signal to downstream effectors. An emerging class of important regulators operating near the top of the DDR cascade consists of the so-called checkpoint mediators (also known as adaptors), a group of large multidomain proteins currently including BRCA1, 53BP1, MDC1/NFBD1 (MDC1), TopBP1 and claspin (Petrini and Stracker, 2003; Kastan and Bartek, 2004; Mochan et al., 2004; Bartek and Mailand, 2006; Stucki and Jackson, 2006) . Whereas claspin and TopBP1 are involved in ATR/Chk1-mediated signalling (Kumagai and Dunphy, 2000; Kumagai et al., 2006; Liu et al., 2006) , the remaining mediator proteins contribute to efficient responses to DNA double strand breaks (DSBs) mediated by ATM (DiTullio et al., 2002; Goldberg et al., 2003; Mochan et al., 2003; Stewart et al., 2003; Ward et al., 2003; Xu and Stern, 2003; Huyen et al., 2004; Lukas et al., 2004a, b; Bekker-Jensen et al., 2005; Stucki et al., 2005; Lou et al., 2006) . Although the precise role(s) and mechanisms of action of the mediator proteins remain to be elucidated, they appear to facilitate interactions between ATM/ATR and their substrates and contribute to spatiotemporal modulation of chromatin around, processing of, and signalling from, the sites of DNA damage Kastan and Bartek, 2004; Mochan et al., 2004; Stucki and Jackson, 2006) .
A large body of experimental and clinical evidence implicates defects of various components of the DDR machinery, including DNA damage sensors, signalling kinases and diverse effectors involved in DNA repair, cell cycle checkpoints, chromatin remodeling as well as cell death pathways, in tumourigenesis (Shiloh, 2003; Kastan and Bartek, 2004; Nevanlinna and Bartek, 2006; Bartek and Lukas, 2007) . This notion is further supported by tumour-prone phenotypes of mouse models with deletions or inactivating mutations in DDRrelated genes . In human tumour pathogenesis, germ-line mutations of genes that encode components of the DDR network, such as BRCA1, BRCA2, p53, Chk2 or ATM, predispose to various types of familial cancer, while somatic mutations in one or more DDR genes contribute to the multistep development of the majority, if not all, sporadic tumours Kastan and Bartek, 2004; Nevanlinna and Bartek, 2006) .
The intimate link between DDR and tumourigenesis has recently been further strengthened by discoveries of constitutive activation of the DNA damage checkpoints in early precursor lesions in several types of human malignancies (Bartkova et al., 2005b; Gorgoulis et al., 2005) . Together with functional analyses of xenograft and cell culture models of oncogene activation, these results suggest that the DDR machinery may serve as an inducible barrier against tumorigenic transformation and/or progression of human cancer. This concept also implies that activated DNA damage checkpoints create an environment in which inactivating mutations within the DDR network are selected for in lesions that eventually overcome the DDR-induced cell death or senescence pathways and progress towards malignancy (Bartkova et al., 2005b Gorgoulis et al., 2005; Di Micco et al., 2006) .
Given such fundamental involvement of the DDR in tumourigenesis, and the fact that major therapeutic modalities currently used to treat cancer, including ionizing radiation and many chemotherapeutics, operate through causing DNA damage, it is imperative to understand better the mechanisms and biological role(s) of the DDR machinery. Here, we attempt to gain more insights into tissue biology and relation to human cancer of two DNA damage checkpoint mediators, MDC1 and 53BP1. Previous work has documented critical roles of both MDC1 and 53BP1 in cellular responses to DSBs, including their requirement for efficient detection and/or timely signalling of DNA lesions, and effects on multiple cell-cycle checkpoints. Preliminary evidence also indicates that the lack of 53BP1 in mice can predispose to tumours (Ward et al., 2005; Morales et al., 2006) , and that a subset of human melanomas and lung carcinomas, the only cancer types examined so far, show defects of 53BP1 at the protein level (Gorgoulis et al., 2005) . On the other hand, there are as yet no reports of analyses of MDC1 in either human or animal tumours. In addition, the tissue distribution and cell type-related expression patterns of either of these two checkpoint mediators in normal tissues remain largely unknown. Our present study was designed to help fill such major gaps in the current knowledge about MDC1 and 53BP1, two important DDR components that protect genomic stability and whose malfunction may contribute to tumourigenesis.
Results
To assess tissue expression patterns by immunohistochemistry on paraffin sections, we first sought to identify reliable antibodies for such application. Whereas a mouse monoclonal antibody suitable for immunoperoxidase detection of 53BP1 in archival tissue specimens is available and was previously used to analyse this protein in human lung and skin tissues (Gorgoulis et al., 2005) , there was no appropriate reagent to examine MDC1. To generate such antibody, rabbits and mice were immunized with purified, recombinant polypeptides corresponding to distinct domains of human MDC1 and the resulting polyclonal (rabbit) and monoclonal (mouse) antibodies characterized in various assays. The mouse antibody DCS-380.1 raised against the C-terminal portion of MDC1 was chosen for subsequent immunohistochemical analyses, based on its ability to detect MDC1 by immunofluorescence and immunoblotting (Supplementary Figure S1 ) and its applicability in immunoperoxidase staining of formalin-fixed, paraffin tissue sections (see below). Importantly, staining of cultured irradiated cells, but not mock-treated control cultures, with DCS-380.1 showed the characteristic formation of radiation-induced foci previously reported for MDC1 (Goldberg et al., 2003; Stewart et al., 2003) . Also, cells in which MDC1 was depleted by siRNA-mediated knockdown lacked the immunostaining signal irrespective of fixation method used (Supplementary Figure S1A and data not shown), thus further supporting the specificity of this reagent for immunostaining applications.
To establish the physiological expression patterns of 53BP1 and MDC1 in vivo, we next performed an immunohistochemical analysis of a wide spectrum of normal human tissues, using the established antibody to 53BP1 (Schultz et al., 2000) , two antibodies against MDC1 (Goldberg et al., 2003) and the Ki67 proliferation marker. Both the 53BP1 and MDC1 proteins were expressed in all tissues examined, including various epithelial, muscle, stromal and neuronal cell types and regardless of the proliferation and differentiation state. Some typical examples of the staining patterns for 53BP1 and MDC1 are shown in Figures 1 and 2 , respectively. Whereas 53BP1 was always nuclear (Figure 1 ), including neurons (Figure 1g ), MDC1 was localized to nuclei in the majority of the tissues (Figure 2 ), yet showed pan-cellular or even preferentially cytoplasmic localization in neuronal cells (Figure 2e ).
An exceptional granular (focal) nuclear staining pattern for both 53BP1 and MDC1 was found in scattered lymphoid cells in normal bone marrow and in adult testis, particularly spermatocytes (Figures 3a-d ).
This contrasted with other tissues and cell types, which showed homogeneous nuclear signal without apparent foci. The focal pattern likely reflects the physiological response to DNA double-strand breaks that occur during meiotic recombination of spermatocytes and immunoglobulin gene rearrangements in lymphocytes (Bassing and Alt, 2004; Bartkova et al., 2005a) . To confirm that foci which form at the site of DSBs, for example in response to ionizing radiation and which are commonly evaluated by immunofluorescence techniques, are detectable also by means of enzyme-based immunohistochemistry, we examined several cultured human cell types by immunoperoxidase staining. Examples shown in
Figures 3e-h demonstrate that, indeed, both the radiation-induced foci and the constitutive foci reported previously in diverse cancer cell lines (DiTullio et al., 2002) are detectable by the immunoperoxidase method that we employ here to analyse human tissues and tumour specimens.
With the suitable antibodies and the immunohistochemical approach validated, we next examined in more detail the staining patterns for 53BP1 ( Figure 4 ) and MDC1 ( Figure 5 ) in a series of normal human breast tissues (n ¼ 56), carcinoma in situ (n ¼ 55) and invasive breast carcinomas (n ¼ 81). Both 53BP1 ( Figure 4a ) and MDC1 ( Figure 5a ) were expressed in nuclei of both normal luminal and basal epithelial cells, as well as in stromal cells and there were no apparent foci formed by either protein. In contrast to almost homogeneous staining in all normal breast tissues and in the majority of the breast carcinomas, we found subsets of tumours in which MDC1 (in 30% of cases) or 53BP1 (in 26%) were aberrantly reduced or lost, as compared to surrounding normal cells (Figures 4e, f and 5c, d) . In addition, among tumours with detectable staining, the pattern was often focal when viewed under higher magnification, reminiscent of cells with activated DNA damage response due to presence of unrepaired DSBs (Figure 4d ).
To compare the breast tumours with other types of cancer, we also examined panels of lung cancer and testicular germ cell tumours, using the same techniques and antibodies and compared with corresponding normal tissues. The results obtained with invasive lung cancer (n ¼ 55) were analogous to those seen in breast tumours, in that both 53BP1 (Figures 6a-c) and MDC1 (Figures 7a and b) proteins were detectable and formed a homogeneous, diffuse (non-focal) pattern in nuclei of normal bronchial and alveolar epithelial cells in all normal lung tissues examined (n ¼ 30). Furthermore, subsets of the lung carcinomas showed abnormally reduced or lost staining for 53BP1 (in 24% of cases; DNA damage response mediators MDC1 and 53BP1 J Bartkova et al Figure 6h ) and MDC1 (in 28%; Figure 7d ), and similar to breast tumours, the staining pattern was sometimes focal, indicating constitutive activation of the DNA damage response (Figure 6f ). Importantly, among the 12 tumours of the breast or lung that showed the most pronounced defect of either 53BP1 or MDC1, the aberrant lack of staining was mutually exclusive for these two DNA damage mediators in all but one case. In sharp contrast to either breast or lung tumours, we found no evidence of aberrant lack of either 53BP1 or MDC1 in any of the human testicular germ cell tumours (n ¼ 43), except for only moderate patchy reduction, especially for 53BP1, in three embryonal carcinomas. Also different from the breast and lung carcinomas was the apparent lack of any testicular tumours with focal staining patterns, except for rare foci among the intratubular malignant cells of the carcinoma in situ of the testis and a small subset of embryonal carcinomas (see Figure 8 for examples). When compared among the three types of human tumours examined in this study, both carcinomas of the breast and lung showed subsets of cases with aberrations of the 53BP1 and MDC1 proteins, while such defects were virtually absent in DNA damage response mediators MDC1 and 53BP1 J Bartkova et al testicular tumours (Figures 9a and b) . The potential reasons for such pronounced differences, their relationship with the cells of origin and the role of DNA damage response in the pathogenesis of these types of malignancies are discussed below.
Discussion
Despite the fact that 53BP1 and MDC1 are emerging as important spatiotemporal regulators of the genome maintenance machinery close to the top of the DNA damage signalling and lesion processing cascades Stucki and Jackson, 2006) , very little is known about their tissue and cell-type expression patterns, and their potential involvement in tumourigenesis. We believe our present study provides significant insights into these aspects of 53BP1 and MDC1 biology and pathology. First, our data show that both proteins are coexpressed in virtually all normal human tissues, and in both proliferating and terminally differentiated, quiescent cells. This global tissue expression pattern is reminiscent of the ATM kinase (Bartkova et al., 2005a) , and similar to, but marginally broader than, the expression pattern of the Chk2 kinase (Lukas et al., 2001; Latella et al., 2004) . Such similarities are consistent with the shared roles of ATM, 53BP1, MDC1 and Chk2 in response to DSBs, and with the function of this pathway also in G 1 and even G 0 phases of the cell 
DNA damage response mediators MDC1 and 53BP1
J Bartkova et al cycle Latella et al., 2004) . These features contrast with those of numerous other DDR proteins whose function is restricted to proliferating cells, and often limited to the S and G 2 phases, such as the ATR-Chk1 signalling module or the homologous recombination machinery, for example (Lukas et al., 2001; Jazayeri et al., 2006) . Since no cell-cycle checkpoint role is needed in response to DNA damage in nonproliferating cells, the ATM/MDC1/53BP1 pathway operating in quiescent tissues probably promotes repair of DSBs to maintain the transcribed genome functional, and/or eliminates cells with irreparable damage through apoptosis.
Apart from response to external genotoxic insults, this pathway also contributes to processing of the DSBs that occur as parts of the physiological programmes of meiotic recombination in spermatogenesis and immunoglobulin class switch or antigen receptor gene recombination during lymphocyte differentiation (Bassing and Alt, 2004) . It is reassuring that activation events of the DSB response machinery, such as autophosphorylation of ATM and phosphorylation of histone H2AX (Bartkova et al., 2005a, b) , as well as foci formation of 53BP1 and MDC1 (this study and Gorgoulis et al., 2005) can be conveniently monitored in vivo by immunohistochemistry. From this point of view, antibodies specific for such activatory phosphoepitopes and/or those detecting the foci formed by the DDR proteins at the sites of DNA lesions, might be regarded as a kind of 'bio-dosimeter' applicable for in situ analyses of biopsy specimens.
Second, we provide evidence for aberrant reduction or loss of 53BP1 and MDC1 in subsets of human carcinomas of the breast and lung, thereby supporting the notion of 53BP1 and MDC1 as emerging candidate tumour suppressors. For 53BP1, such a notion is so far supported by the tumour-prone phenotype of 53BP1-deficient mice (Ward et al., 2005; Morales et al., 2006) , as well as aberrant absence of the protein in subsets of human lung tumours and melanomas (Gorgoulis et al., 2005) . On the other hand, the recently reported MDC1 gene knockout mice have not been analysed for tumour incidence so far (Lou et al., 2006) and, owing to the lack of suitable reagents, there have been no reports on MDC1 protein expression in tissues or tumours. Clearly, additional work is required to examine the candidacy of 53BP1 and MDC1 as tumour suppressors. On the other hand, such a possibility is also consistent with the fact that aberrations in other components of the DSB response pathway, including ATM, Chk2, H2AX, the Mre11/Rad50/Nbs1 complex, BRCA1 or p53 are all known to predispose to, or contribute to progression of, various forms of cancer Nevanlinna and Bartek, 2006) .
Third, our present results further strengthen and extend the recently proposed concept of DDR activation as an inducible biological barrier against progression of human tumours beyond their early, preinvasive stages (Bartkova et al., 2005b; Gorgoulis et al., 2005; Bartek and Lukas, 2007) . This concept reflects the documented frequent constitutive activation of the DDR network in various types of major human tumours, and the ability Figure 9 Summary of 53BP1 and MDC1 immunohistochemical data from three types of human tumours: carcinomas of the breast and lung, and testicular germ-cell tumours. (a and b) Graphical summaries of the frequencies of reduced/lacking MDC1/53BP1 proteins and activation (foci formation), respectively. The 90 normal tissues include 56 breast, 30 lung tissues and four normal testes samples (the testicular germ-cell tumours (TGCTs) originate from early gonocytes, while in adult testes, the DDR machinery is activated during meiotic recombination, as shown in Figure 4 ). Among TGCTs, there was a moderate patchy reduction of MDC1/ 53BP1 staining and focus formation in three of the embryonal carcinomas tested, but of lower degree than the aberrations scored in lung or breast tumours). (c) Schematic illustration of the major differences between breast and lung cancer on one hand, and TGCTs on the other, in terms of the DDR activation and 53BP1/MDC1 loss, considered within the framework of the DDR machinery as an anti-cancer barrier and selective pressure for DDR defects that facilitate tumour progression.
of an ever increasing spectrum of known oncogenes (Bartkova et al., 2005b Gorgoulis et al., 2005; Di Micco et al., 2006; Pusapati et al., 2006; Tort et al., 2006) , as well as telomere attrition (d'Adda di Fagagna et al., 2003; Takai et al., 2003) , to elicit the DDR activation in both cell culture and mouse tumour models. The concept also postulates that the cell death and cell cycle arrest/senescence that impose the barrier against tumour progression as a result of the activated DNA damage checkpoints represent a major source of selection pressure for tumour-promoting mutations such as those in p53 and other DDR components, that allow rescue of tumour cell proliferation at the expense of increasing genetic instability and cancer progression (Bartkova et al., 2005b Gorgoulis et al., 2005; Di Micco et al., 2006) . What is also common to human tumours is that the extent of the constitutive DDR activation and signalling is greater in the preinvasive lesions compared with the overtly malignant tumours. This decreased DDR signalling in later stages of tumour progression may be caused by several factors, such as the tumour-acquired defects within the upstream DDR sensing or signalling machinery, aberrantly enhanced DNA repair and/or activation of telomerase. The advanced malignancies with such persistent DDR signalling had likely suffered inactivating mutations downstream within the DDR machinery, such as in p53 or other apoptosis or cell-cycle arrest effectors, which allow survival and tumour growth despite the ongoing futile checkpoint signalling.
So how do the present data on 53BP1 and MDC1 fit the above concept? The scenario observed in breast and lung tumours fits very well, as we observed activation (foci formation) in subsets of cases, and also aberrant reduction or lack of these DDR components, consistent with the idea of selection for such defects to escape the imposed barrier. In this context, it is also significant that among the 12 cases with the most pronounced defects of either MDC1 or 53PB1, such defects (except in one case) were always mutually exclusive, suggesting that one defect in the common pathway of MDC1-53BP1 (Bekker-Jensen et al., 2005; Stucki and Jackson, 2006) was sufficient to deregulate this mechanism.
The testicular germ cell tumours are exceptional among the types of human malignancies tested for constitutive DDR activation so far, in that this phenomenon occurs only rarely. This conclusion is supported by the apparent lack of 53BP1/MDC1 foci in these tumours seen in the present study, as well as by the paucity of ATM activation and gH2AX in both the human testicular carcinoma in situ precursor lesions as well as among the invasive testicular germ-cell tumours (TGCTs) (Bartkova et al., 2005a) . This difference between TGCTs and the other major solid cancers may reflect several factors, including the unique origin from early germ cells (as opposed to somatic cells), distinct spectra of oncogenes involved and longer telomeres, all specific features of the former tumours (Albanell et al., 1999; Nowak et al., 2000; Bartkova et al., 2003; Rajpert-De Meyts et al., 2003; Oosterhuis and Looijenga, 2005; Rajpert-De Meyts, 2006) . Importantly, whatever the reasons for the low incidence of spontaneous DDR activation in TGCTs may be, this correlates well with the low frequency of defects in DDR components such as p53 (Lutzker and Levine, 1996; Oosterhuis and Looijenga, 2005) or the loss of 53BP1/ MDC1 (this study). The difference in terms of constitutive DDR activation and its impact in TGCTs, as opposed to other solid human tumours (such as carcinomas of the breast or lung), is schematically depicted in Figure 9c . The overall correlation between DDR activation and defects in DDR components such as p53, as seen in carcinomas, or the concomitant lack of DDR activation and defects (as seen in TGCTs) further supports the concept of the DDR barrier as a selection pressure to favour DDR defects such as p53 mutations during tumour progression.
Last but not least, the ability to monitor the status of activation and defects within the DDR machinery may help optimize therapeutic decisions in the clinic. As the major non-surgical treatment modalities used in contemporary oncology, ionizing radiation and chemotherapy mostly rely on causing DNA damage, individual assessment of the cellular machinery that primarily responds to such insults, both in the patient and the tumour, may prove beneficial for personalized medicine approaches in the future.
Materials and methods

Antibodies
Mouse monoclonal antibodies against human MDC1 were generated by immunizing Balb/c mice with the recombinant, bacterially expressed and gel-purified C-terminal fragment of human MDC1/NFBD1 protein. Fusion with NS2 mouse myeloma cells yielded a number of hybridomas from which the clone DCS380.1 was selected for further studies (see Results). The additional immunoreagents used in this study included rabbit (#889 and #1987) and sheep (#3835) polyclonal antibodies against distinct domains of human MDC1 (Goldberg et al., 2003; and unpublished data) , mouse monoclonal antibody to 53BP1 (Schultz et al., 2000 ; a gift from TD Halazonetis), and rabbit polyclonal antibody to the Ki67 proliferation marker (Dako, Glostrup, Denmark).
Cell culture, RNA interference, irradiation and immunofluorescence The human U-2-OS sarcoma cell line and WI38 primary fibroblast cell strain were cultured in Dulbecco's modified Eagle's medium (Biowhittaker, Copenhagen, Denmark) supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA) and antibiotics. Depletion of MDC1 in live cells was achieved by siRNA mediated knockdown approach, using previously published siRNA duplexes and protocols (Goldberg et al., 2003; Lukas et al., 2004a) . In some experiments, cells were exposed to ionizing radiation (IR, 15Gy). IR was delivered by an X-ray generator (Pantak HF160, 150 kV; 15 mA; dose rate 2.18 Gy/min). One hour after irradiation, mock-treated and irradiated cells grown on glass coverslips were fixed in 4% buffered formaldehyde and examined by immunofluorescence as described (Bekker-Jensen et al., 2005).
Immunoblotting
The cell lysates were separated on sodium dodecyl sulphatepolyacrylamide gel electrophoresis and electroblotted onto nitrocellulose membrane. Membranes were incubated with anti-ATM 1981S-P or anti-Flag M5 (Sigma, Vallensbaek, Denmark). Immunoblots of soluble cell extracts were prepared and probed with antibodies against MDC1 as reported earlier (Horejsi et al., 2004) .
Normal tissues and tumours
Tumors and normal tissues were provided by the tissue banks of the participating Institutes in Denmark and Norway, with a consent from the local ethical committees. Multiple biopsy specimens of the majority of normal tissue types were included in the study, resected either for cosmetic reasons or benign conditions, or taken from a margin of the specimen as far from the tumour as possible when the biopsy was taken for a tumour. To ensure optimal preservation of the analysed protein epitopes, no necropsy specimens were included in our study. The testicular tumour specimens were from routine diagnostic or therapeutic surgery, while the fetal testes samples were from approved abortions and the normal adult testes were from a preserved tissue margin removed during orchidectomy due to a non-germinal cell testicular tumour or for prostate cancer.
Immunohistochemistry on paraffin sections Indirect immunoperoxidase staining was carried out using formaldehyde-fixed, paraffin embedded tissue sections mounted on poly-L-lysine-coated or electrostatically treated slides. For antigen unmasking, the deparaffinized sections were boiled in a microwave oven for 10-15 min in citrate buffer (0.01 M citric acid monohydrate, pH 6.0) before initiating the staining procedure. The sensitive immunoperoxidase staining method was performed as described (Lukas et al., 2001) , using the Vectastain Elite kit (Vector Laboratories, Burlingame, CA, USA) to detect the primary antibodies, and a nickel sulphateenhancement step without nuclear counterstaining to visualize the chromogenic (diaminobenzidine) reaction and detect even moderate nuclear signals. The immunostaining patterns were evaluated by an experienced pathologist. Since at least 90 and 80-85% of cells in normal tissues were positive for 53BP1 and MDC1, respectively, we considered the results in cancer specimens as still normal when more than 70% (for 53BP1) or over 65% (for MDC1) cancer cells were stained. The staining patterns of tumours were regarded as aberrantly reduced when only 40-70% of cancer cells were positive for 53BP1 and 35-65% for MDC1, while we considered as aberrant loss of 53BP1 and MDC1 when 0-39 and 0-34% of cancer cells were stained, respectively, in contrast to positive staining of the surrounding normal or stromal cells on the same section.
